Placebo-controlled trial of house dust mite-impermeable mattress covers: effect on symptoms in early childhood

Laurens P. Koopman, Rob T. van Strien, Marjan Kerkhof, Alet Wijga, Henriette A. Smit, Johan C. de Jongste, Jorrit Gerritsen, Rob C. Aalberse, Bert Brunekreef, Herman J. Neijens

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We investigated the effect of house dust mite (HDM)-allergen avoidance on the development of respiratory symptoms, atopic dermatitis, and atopic sensitization by performing a double blind, placebo-controlled trial. In total, 1,282 allergic pregnant women were selected (416 received HDM allergen-impermeable mattress covers for the parents' and child's mattress in the third trimester of pregnancy [active], 394 received placebo covers, 472 received no intervention). Data on allergen exposure, clinical symptoms, and immunoglobulin E were collected prospectively. The prevalence of night cough without a cold in the second year of life was lower in the group with active covers compared with the group with placebo covers (adjusted odds ratio 0.65; 95% confidence interval 0.4-1.0). No effect of the intervention was seen on other respiratory symptoms, atopic dermatitis, and total and specific immunoglobulin E. It can be concluded that application of HDM-impermeable mattress covers on the child's and parents' beds reduced night cough, but not other respiratory symptoms, atopic dermatitis, and atopic sensitization in the first 2 years of life. Follow-up will determine the long-term effect of the intervention on the development of atopic disease
Original languageEnglish
Pages (from-to)307-313
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume166
Issue number3
DOIs
Publication statusPublished - 2002

Cite this